moderna

Propionic acidemia (PA)

Last program update: May 7, 2020

Modality	ID #	Program *Indication*	Preclinical development	Phase 1	Phase 2	Phase 3 and commercial	Moderna rights
Systemic intracellular therapeutics	mRNA-3704	MUT *Methylmalonic acidemia, MMA* 					Worldwide
	mRNA-3927	PCCA/PCCB *Propionic acidemia, PA* 					Worldwide
	mRNA-3283	PAH *Phenylketonuria, PKU* 					Worldwide
	mRNA-3745	G6Pase *Glycogen storage disease type 1a, GSD1a* 					Worldwide

Due to the COVID-19 pandemic, new enrollment and new site initiation for its Phase 1/2 study of mRNA-3927 has been paused

Organic acidemias

Multiple candidates targeting same metabolic pathway



MMA and PA

- Similar biology and disease pathology
- Shared KOLs and centers of excellence
- Relative prevalence in any given locale is a function of local founder effects/ consanguinity
  - MMA: ~500-2,000 patients in the US*
  - PA: ~325-2,000 patients in the US*

mRNA advantages

*Ability to encode for **intracellular** proteins, **localized** to mitochondria*

*Potential to treat during **acute** metabolic decompensations*

*Based on estimated birth prevalence (MMA: 0.3-1.2:100,000 newborns; PA: 0.2-1.2:100,000 newborns) and mortality rates

Last updated: May 7, 2020

moderna

Propionic acidemia (PA) (mRNA-3927)

Preclinical data show restoration of enzyme activity

Study Design:

Species: Mouse

- Animals: PA^
- Dose: 1 mpk (A); 1 mpk (B); 0.5-1 mpk (C)
- Dosing Schedule: Single (A); approximately monthly for doses 2-6[1] (B,C)
- Injection Route: IV
- Sample Size: 4-5/group (A); 6/group (B,C)

Reduction in plasma ammonia with PCCA+PCCB mRNA



(A)

Reduced plasma 2-methylcitrate levels with repeat dosing of PCCA+PCCB mRNA



(B)

Data presented as mean ± standard deviation.

Decrease in heart weight with PCCA+PCCB mRNA in 6 month repeat dose study



(C)

Data presented as mean ± standard deviation.

We have demonstrated pre-clinical proof-of-concept for combined PCCA and PCCB mRNA therapy in in vivo studies

^Pcca-/-(A138T) mice (Guenzel et al Mol Ther 2013)

[1] Biomarkers monitored for 7 weeks after first dose to determine duration of response, then approximately monthly dosing

Last updated: May 7, 2020

moderna

Clinical development plan

Combined natural history study, and two Phase 1/2 MAD studies in pediatric MMA and PA patients

Global natural history study:

- Enrollment in the study has been completed for MMA and PA
- Identifying and correlating clinical and biomarker endpoints
- Global, multi-center, non-interventional study:
  - —Patients confirmed with MMA due to MUT deficiency or PA
  - —Up to 60 MMA patients and up to 60 PA patients in the US and Europe will be followed prospectively for 1-3 years
  - —Retrospective data to be collected as available

2 Phase 1/2 clinical trials, for mRNA-3704 in MMA and mRNA-3927 in PA:

- Open-label, multi-center, dose escalation Phase 1/2 study (US and Europe)
- **Objectives**
  - —Evaluate safety and tolerability
  - —Characterize the pharmacodynamic response
  - —Characterize the pharmacokinetic profile
  - —Assess incidence of clinical events

mRNA-3704 (MMA) and mRNA-3927 (PA) have both received FDA Fast Track designation, FDA orphan drug designation, FDA rare pediatric disease designation and EMA orphan drug designations

Forward-looking statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended including, but not limited to, statements concerning potential development candidate applications, development candid ate activities, preclinical and clinical studies, regulatory submissions and approvals, risk management and estimates and forward -looking projections with respect to Moderna or its anticipated future performance or events. In some cases, forward -looking statements can be identified by terminology such as “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimat es,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward -looking statements contain these words. The forward-looking statements in this presentation are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward -looking statements. These risks, uncertainties and other factors include, among others: preclinical and clinical development is lengthy and uncertain, especially for a new category of medicines such as mRNA, and therefore Moderna’s preclinical programs or development candidates may be delayed, terminated, or may never advance to or in the clinic; no mRNA drug has been approved in this new p otential category of medicines, and may never be approved; mRNA drug development has substantial clinical development and regulatory r isks due to the novel and unprecedented nature of this new category of medicines; and those described in Moderna’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent filings made by Moderna with SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements in this presentation in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.

moderna